SGEN Seagen
WatchlistSeagen News
Seagen Says Phase 2 Trial of Hodgkin Lymphoma Therapy Showed 'Clinically Meaningful Progression-Free Survival'
Seagen (SGEN) said Sunday a phase 2 study assessing Adcetris combined with nivolumab and certain chemotherapy agents showed "clinically meaningful progression-free survival" in patients with classical
Express News | Seagen's ADCETRIS Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival At 12 Months In Phase 2 Trial Of Patients With Early Stage Classical Hodgkin Lymphoma
ADCETRIS (Brentuximab Vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 Months in Phase 2 Trial of Patients With Early Stage Classical Hodgkin Lymphoma
Seagen Inc. (NASDAQ:SGEN) today announced that clinically meaningful progression-free survival (PFS), a secondary endpoint, was observed in a Phase 2 study evaluating the antibody-drug conjugate (ADC) ADCETRIS® (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (AN+AD) as first-line treatment for early and advanced stage classical Hodgkin lymphoma (cHL).
Biotech Deals Are Heating Up. 2024 Could Be Even Hotter for M&A.
The year-end spurt of biopharma mergers and acquisitions bodes well for the sector in 2024.
$100 Invested In Seagen 20 Years Ago Would Be Worth This Much Today
Seagen (NASDAQ:SGEN) has outperformed the market over the past 20 years by 11.34% on an annualized basis producing an average annual return of 18.82%. Currently, Seagen has a market capitalization of
Top Stocks With Highest Hedge Fund + Mutual Fund Positions, According to GS
Seagen Says Tukysa Plus Kadcyla Showed 'Significant Improvement" in Breast Cancer Patients' Progression-Free Survival
Seagen (SGEN) said Wednesday that results from a phase 3 trial of Tukysa plus Kadcyla showed the combination demonstrated a "statistically significant improvement" in progression-free survival, which
Seagen's Breast Cancer Drug Shows Positive Results in Combination Therapy Trial
Seagen: HER2CLIMB-02 Study Results Reinforce Clinical Activity Of TUKYSA
TUKYSA (Tucatinib) in Combination With Antibody-Drug Conjugate Ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer
Seagen Inc. (NASDAQ:SGEN) today announced data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla®).
Seagen Gains Amid Options Trades, Optimism for FTC Approval for Pfizer Deal
Biotechs Post Record Gains in November Amid Improving Outlook
FDA to Decide on Approving Keytruda/Padcev Combo Therapy by May 9
Merck Says FDA Grants Priority Review to Application for Keytruda Plus Padcev for Urothelial Cancer Treatment
Merck (MRK) said late Thursday that the US Food and Drug Administration accepted for priority review a new supplemental biologics license application seeking approval for a combination of Keytruda and
Express News | Seagen Says FDA Grants Priority Review For Supplemental Biologics License Application (SBLA) Of PADCEV (Enfortumab Vedotin-ejfv) With KEYTRUDA (Pembrolizumab) For First-Line Treatment Of Advanced Bladder Cancer
AbbVie to Acquire Cancer Drugmaker ImmunoGen for $10B Cash
Pfizer CFO Reiterates Seagen Closing Expected Later This Year, Early Next Year
Unusual Options Activity: LEGN, SGEN and Others Attract Market Bets, LEGN V/OI Ratio Reaches 1000.0
EST Nov 27th Closing Delivery - In the last 3 hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.Of
Daiichi Sankyo Wins Favorable Final Arbitration Ruling in Dispute With Seagen
Daiichi Sankyo (TYO:4568) received a favorable final arbitration ruling in an intellectual property dispute with Seagen, according to a Monday bourse filing. Seagen was ordered to pay about $45.5 mill
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,600 Today
Seagen (NASDAQ:SGEN) has outperformed the market over the past 5 years by 17.92% on an annualized basis producing an average annual return of 29.45%. Currently, Seagen has a market capitalization of $